CRKL
protein-codingCRK like proto-oncogene, adaptor protein, the group of SH2 domain containing
Gene summary
This gene encodes a protein kinase containing SH2 and SH3 (src homology) domains which has been shown to activate the RAS and JUN kinase signaling pathways and transform fibroblasts in a RAS-dependent fashion. It is a substrate of the BCR-ABL tyrosine kinase, plays a role in fibroblast transformation by BCR-ABL, and may be oncogenic.[provided by RefSeq, Jan 2009]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~36.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: Unknown
Disease ID:MONDO:0005453
Submitter: ClinGen
*CRKL* was first reported in relation to congenital heart disease in 2012 (Tomita Mitchell et al., PMID:22318994). Seven probands with CNVs (4 duplications, 3 gross deletions) at the 22q11.2 location have been reported in 3 publications (PMID: 22318994, 28121514, 36205932). No evidence for a causal role for *CRKL* in congenital heart disease has been reported. Although this gene-disease association is supported by an animal model, no reports have directly implicated the gene in humans. This classification was approved by the ClinGen Congenital Heart Disease GCEP on the meeting date 10/17/2023 (SOP Version 9)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CRKL variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005207.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 25 | 1 | 26 | |||
| missense | 22 | 1 | 23 | |||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 2 | 2 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 0 | 0 | 25 | 25 | 2 | 52 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005198.1 | 3 | MANE Select | |
| Ensembl | ENSP00000346300.3 | 3 | MANE Select | |
| Ensembl | ENSP00000396646.1 | 3 | Standard | |
| Ensembl | ENSP00000564758.1 | 3 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| crkl | Danio rerio | Structure: fast muscle cell Quality: mononucleate abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Chronic myeloid leukemia - Homo sapiens (human)
- Focal adhesion - Homo sapiens (human)
- Fc gamma R-mediated phagocytosis - Homo sapiens (human)
- Renal cell carcinoma - Homo sapiens (human)
- Neurotrophin signaling pathway - Homo sapiens (human)
Biological Process
- activation of MAPKK activity
- activation of MAPK activity
- regulation of cell growth
- blood vessel development
- urogenital system development
Molecular Function
- phosphotyrosine residue binding
- RNA binding
- SH3/SH2 adaptor activity
- protein binding
- identical protein binding
Cellular Component
- nucleoplasm
- cytosol
- neuromuscular junction
- protein-containing complex
- extrinsic component of postsynaptic membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000354336
- Coding exons
- 3
- Length
- 36324
- Individuals with no LoFs
- 125740
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 4
- Defined
- 125744
- p
- 0.0000159
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.94 | 105 | 178 | 0.591 | 0.00000943 | 1973 |
| Missense (PolyPhen) | 23 | 68.177 | 0.33736 | 767 | ||
| Synonymous | -2.03 | 98 | 75.6 | 1.30 | 0.00000447 | 633 |
| Loss of Function | 2.31 | 2 | 9.82 | 0.204 | 4.23e-7 | 118 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000027 | 0.000026 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: May mediate the transduction of intracellular signals.;
Recessive Scores
- pRec
- 0.440
Intolerance Scores
- LoFtool
- 0.0613
- RVIS EVS
- -0.32
- RVIS percentile EVS
- 31.46
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- E
- Essential (gene trap)
- H
- Indispensability pred.
- E
- Indispensability score
- 1.00
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |